Posts Tagged 'invokana'

Invokana May Actually Increase Risk of Diabetes Amputations

invokana may increase risk of diabetes-related amputationsThe effects of diabetes on a patient’s body are numerous and wide-ranging. In some cases, the inability to regulate insulin production is the only impact and is resolved in a seemingly simple way. Injection, diet, or an insulin pump that be used to take over sugar regulation for the diabetic. In other cases, however, the patient’s battle is an arduous one and strict compliance with physicians’ instructions is the ...

continue reading...

Lopez McHugh Files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury

PHILADELPHIA (December 2015) – The national trial lawyers of Lopez McHugh have filed a lawsuit against Johnson & Johnson and its subsidiary, Janssen, alleging that its diabetes medication, Invokana®, causes patients to develop diabetic ketoacidosis.

The lawsuit (Case No. 15-12-00653) was filed in the Court of Common Pleas, Philadelphia County, and includes allegations that the manufacturers of Invokana knew that the drug could cause diabetic ketoacidosis but failed to warn doctors.

Diabetic ketoacidosis is a condition where the body produces ketones, ...

continue reading...

Woman Claims Invokana Caused Her Diabetic Ketoacidosis

A Georgia woman has filed an Invokana ketoacidosis lawsuit claiming Janssen Pharmaceutical’s drug caused her to develop the potentially life-threatening blood condition known as diabetic ketoacidosis.

Invokana (canagliflozin) is one of a new line of diabetes medications called sodium-glucose cotransport-2 (SLGT2) inhibitors. Unlike traditional insulin treatments, SGLT2 inhibitors regulate the body’s blood sugar levels by reabsorbing excess glucose in the kidneys and disposing of it through urine. Less than two years after Invokana, Farxiga, and Jardiance ...

continue reading...

New Study Shows Higher Rate of Diabetic Ketoacidosis with Invokana

diabetic ketoacidosis more prevalent with invokingA new study from the American Diabetes Association journal Diabetes Care found that Type 1 diabetes patients who took Invokana (canagliflozin) alongside insulin therapy were more likely to experience diabetic ketoacidosis. Diabetic ketoacidosis is a severe and potentially fatal blood condition that develops when too many blood acids, or ketones, are present in the body.

Invokana, which is manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals, belongs to a ...

continue reading...

Invokana Class-Action Lawsuit Filed in Canada

The diabetes drug Invokana has become the focus of a national class-action lawsuit in Canada, CBC Nova Scotia reports. According to a statement filed in the Ontario Supreme Court of Justice, the lead plaintiff alleges that Janssen Pharmaceuticals’ new sodium-glucose cotransporter-2 (SGLT2) inhibitor was responsible for her kidney failure.

SGLT2 inhibitors, a new line of type 2 diabetes medications, work by directing excess blood sugars to be eliminated through urine. But not long after they reached the ...

continue reading...

First Study on SGLT2 Inhibitor Use in Type 1 Diabetics Shows Increased Diabetic Ketoacidosis

sglt2 inhibitor results fall shortAccording to a Medscape article, the results of the first-ever Phase 2 study of sodium-glucose cotransporter-2 (SGLT2) inhibitor use in type 1 diabetes patients have been reported—and they may not be as reassuring as many had hoped. The data were presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting by Robert R. Henry, MD, chief of the Division of Endocrinology and Metabolism at the University ...

continue reading...
Page 2 of 3 123